Open-label pilot study of levetiracetam (Keppra) for the treatment of levodopa-induced dyskinesias in Parkinson's disease

Movement Disorders

Volumn 20, Issue 9, 2005, Pages 1205-1209

  Zesiewicz, Theresa A ^a,b   Sullivan, Kelly L ^a,b   Maldonado, John L ^b,c   Tatum, William O ^b   Hauser, Robert A ^a,b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Dyskinesia; Keppra; Levetiracetam; Levodopa; Parkinson's disease

Indexed keywords

AMANTADINE; ANTIPARKINSON AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; ETIRACETAM; LEVODOPA; PRAMIPEXOLE; ROPINIROLE; SELEGILINE; TOLCAPONE; TRIHEXYPHENIDYL;

AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONFUSION; DISABILITY; DIZZINESS; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSKINESIA; FEMALE; HUMAN; LONG TERM CARE; MALE; ON OFF PHENOMENON; OPEN STUDY; OUTCOMES RESEARCH; PARKINSON DISEASE; PILOT STUDY; PRIORITY JOURNAL; SOMNOLENCE; TIME; TREATMENT OUTCOME; WAKEFULNESS;

AGED; ANTICONVULSANTS; ANTIPARKINSON AGENTS; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE; PILOT PROJECTS; PIRACETAM;

EID: 23644462322     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.20563     Document Type: Article

References (26)

1. Hirsch E, Graybiel AM, Agid YA. Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature 1988;334:345-348.
2. Mones RJ, Elizan TS, Siegel GJ. Analysis of L-dopa induced dyskinesias in 51 patients with parkinsonism. J Neurol Neurosurg Psychiatry 1971;34:668-673.
3. Adler CH. Relevance of motor complications in Parkinson's disease. Neurology 2002;58(4 Suppl. 1):S51-S56.
4. Cereghino JJ, Biton V, Abou-Khalil B, et al. Levetiracetam for partial seizure: results of a double-blind, randomized clinical trial. Neurology 2000;55:236-242.
5. Hill MP, Bezard E, McGuire SG, et al. Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L-dopa and ropinirole in the MPTP-lesioned marmoset. Mov Disord 2003;18:1301-1305.
6. Bezard E, Hill MP, Crossman AR, et al. Levetiracetam improves choreic levodopa-induced dyskinesia in the MPTP-treated macaque. Eur J Pharmacol 2004;485:159-164.
7. Frucht SJ, Louis ED, Chuang C, Fahn S. A pilot tolerability and efficacy study of levetiracetam in patients with chronic myoclonus. Neurology 2001;57:1112-1114.
8. Chatterjee A, Louis ED, Frucht S. Levetiracetam in the treatment of paroxysmal kinesiogenic choreoathetosis. Mov Disord 2002;17: 614-615.
9. Zesiewicz TA, Louis ED, Sullivan KL, et al. Substantial improvement in a Meige's syndrome patient with Levefiracetarn treatment. Mov Disord 2004;19:1518-1521.
10. Fahn S, Elton RL, members of the UPDRS Development Committee. Unified Parkinson's disease rating scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, editors. Recent developments in Parkinson's disease, vol. 2. Florham Park, NJ: Macmillan Health Care Information; 1987. p 153-164.
11. Hauser RA, Friedlander J, Zesiewicz TA, et al. A home diary to assess functional status in patients with Parkinson's disease with motor fluctuations and dyskinesia. Clin Neuropharmacol 2000;23:75-81.
12. Hauser RA, Deckers F, Lehert P. Parkinson's disease home diary: further validation and implications for clinical trials. Mov Disord 2004; 19:1409-1413.
13. Guy W. ECDEU assessment manual for psychopharmacology. Washington, DC: Public Health Service, US Department of Health, Education and Welfare; 1976.
14. Guy W. ECDEU assessment manual for psychopharmacology, revised. Rockville, MD, U.S. Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs; 1976. p 218-222.
15. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 1991;14:540-545.
16. Physicians' desk reference, 58th ed. Montvale, NJ: Thompson PDR; 2004.
17. Ondo WG, Dat Vuong K, Khan H, et al. Daytime sleepiness and other sleep disorders in Parkinson's disease. Neurology 2001;57:1392-1396.
18. Tan EK, Lum SY, Fook-Chong SM, et al. Evaluation of somnolence in Parkinson's disease: comparison with age- and sex-matched controls. Neurology 2002;58:465-468.
19. Tandberg E, Larsen JP, Karlsen K. A community-based study of sleep disorders in patients with Parkinson's disease. Mov Disord 1998;13:895-899.
20. Shannon KM, Bennett JP, Friedman JH, for the Prampexole Study Group. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. Neurology 1997;49:724-728.
21. Adler CH, Sethi KD, Hauser RA, et al., for the Ropinirole Study Group. Ropinirole for the treatment of early Parkinson's disease. Neurology 1997;49:393-399.
22. Chase TN, Oh JD, Konitsiotis S. Antiparkinsonian and antidyskinetic activity of drugs targeting central glutarnatergic mechanisms. J Neurol 2000;247(Suppl. 2):1136-1142.
23. Loscher W, Richter A. The glycine/NMDA receptor ligand (+)-HA-966 but not D-cycloserine has potent antidystonic efficacy in a genetic animal model of dystonia. Fur J Pharmacol 1993;239:245-247.
24. Verhagen Metman L, Del Dotto P, van den Munckhof P, et al. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology 1998;50:1323-1326.
25. Hill MP, Ravenscroft P, Bezard E, et al. Levetiracetam potentiates the antidyskinetic action of amantadine in the 1-methyl4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease. J Pharmacol Exp Ther 2004;3 10:386-394.
26. Thomas A, Iacono D, Luciano AL, et al. Duration of amantadine benefit on dyskinesia of severe Parkinson's disease. J Neurol Neurosurg Psychiatry 2004;75:141-143.